Table 1

Study series including ID sample, type of preparation and staining, morphological diagnosis, percentage of neoplastic cells, reference methods and Idylla EGFR Mutation Assay outcome

ID sample	Type of preparation	Staining	Diagnosis	% NC	Reference methods	Idylla EGFR Mutation Assay
1	PE	Pap	ADC	5–24	p.E746_A750del	Del 19
2	FNA	Pap	Favour ADC	5–24	p.L747_S572del	Del 19
3	FNA	Pap	ADC	5–24	p.L858R	ND
4	FNA	H&E	ADC	50	p.LREA	Del 19
5	FNA	H&E	Favour ADC	5–24	p.E746_A750del	Del 19
6	FNA	IHC	NOS	5	p.E746_A750del	ND
7	FNA	H&E	NOS	≥50	WT	ND
8	FNA	H&E	NOS	≥50	p.E746_A750del	Del 19
9	FNA	H&E	ADC	≥50	WT	p.G719X
10	FNA	Pap	Favour ADC	5–24	WT	Invalid
11	FNA	H&E	Favour ADC	≥50	WT	Invalid
12	FNA	H&E	ADC	5–24	WT	ND
13	BB	Pap	Favour ADC	5–24	p.E746_A750del	Del ex 19
14	FNA	Pap	ADC	≥50	WT	ND
15	FNA	Diff Quik	ADC	5–24	WT	ND
16	PE	H&E	ADC	5–24	WT	ND
17	FNA	H&E	Favour ADC	5	WT	Invalid
18	PE	H&E	ADC	≥50	WT	ND
19	FNA	Pap	NOS	5–24	WT	Invalid
20	FNA	H&E	ADC	5–24	WT	ND
21	FNA	Pap	ADC	≥50	WT	ND
22	FNA	H&E	ADC	5–24	WT	ND
23	FNA	Diff Quik	ADC	≥50	p.L858R	p.L858R
24	FNA	H&E	ADC	25–49	WT	ND
25	FNA	H&E	Favour ADC	5–24	WT	p.G719X
26	FNA	Pap	Favour ADC	≥50	WT	Invalid
27	FNA	H&E	NOS	5	WT	ND
28	FNA	Pap	SqCC	25–49	WT	ND
29	FNA	H&E	NOS	5–24	WT	ND
30	PE	Diff Quik	ADC	25–49	WT	ND
31	FNA	Diff Quik	ADC	≥50	WT	Invalid
32	FNA	H&E	Favour ADC	≥50	WT	ND
33	FNA	Diff Quik	ADC	≥50	p.E746_A750del	Del 19
34	FNA	Diff Quik	ADC	≥50	p.E746_A750del	Del 19
35	PE	H&E	ADC	≥50	p.E746_A750del	Del 19
36	FNA	H&E	ADC	≥50	WT	ND
37	FNA	H&E	ADC	≥50	p.E746_A750del	Del 19
38	FNA	Pap	Favour ADC	25–49	p.L858R	ND
39	FNA	H&E	ADC	25–49	WT	ND

ADC, adenocarcinoma; BB, bronchial brushing; FNA, fine-needle aspiration;IHC, immunohistochemistry; NC, neoplastic cellularity; ND, no mutation detected; NOS, not otherwise specified; PE, pleuric effusion; Pap, Papanicolaou; SqCC, squamous cell carcinoma; WT, wild-type.